Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion type Assertion NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_head.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion description "[We recommend that HNF4A sequencing is considered in all patients with diazoxide responsive HH diagnosed in the first week of life irrespective of a family history of diabetes, once K(ATP) channel mutations have been excluded.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_provenance.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion evidence source_evidence_literature NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_provenance.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion SIO_000772 20164212 NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_provenance.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion wasDerivedFrom befree-20140225 NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_provenance.
- NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_assertion wasGeneratedBy ECO_0000203 NP367586.RAvasDxik78fC2Zv91hc7vnYC8Y9RiVVrDF_RxW3t0Kig130_provenance.